<DOC>
	<DOCNO>NCT00434967</DOCNO>
	<brief_summary>The aim compare blood pressure lower effect combination candesartan cilexetil ( candesartan ) 32 mg hydrochlorothiazide ( HCT ) 25 mg candesartan 32 mg alone , HCT 25 mg alone placebo hypertensive adult .</brief_summary>
	<brief_title>Antihypertensive Efficacy Safety Candesartan/HCT 32/25 mg Comparison With Individual Components Placebo</brief_title>
	<detailed_description />
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Patients eligible enrolment study ( Visit 1 ) fulfil follow criterion : Provision sign Informed Consent Primary hypertension , untreated treat maximum 2 antihypertensive drug ( substance ) , patient physician willing withdraw enrolment replace placebo . Mean sit DBP 90114 mmHg ( value calculate eCRF ) Visits 1 2 Patients eligible randomisation ( Visit 4 ) fulfil follow criterion : Mean sit DBP 90114 mmHg ( value calculate eCRF ) end 4week singleblind placebo runin period . The runin period shorter 4 week . Pregnant lactate woman , woman childbearing potential practising adequate method contraception eg , intrauterine device , oral contraception progesterone implant . Pregnancy must exclude negative pregnancy test Visit 1 . Secondary malignant hypertension Sitting SBP 180 mmHg Myocardial infarction , stroke , coronary bypass surgery transient ischaemic attack within 6 month enrolment Angina pectoris require treatment shortacting nitrate Chronic use NSAIDs Aortic mitral valve stenosis Cardiac failure require treatment Cardiac arrhythmia require treatment Gout Renal artery stenosis kidney transplantation Intravascular volume depletion Hypersensitivity component investigational product sulphonamide derive drug Concomitant disease may interfere assessment patient Past present alcohol drug abuse , condition associate poor compliance opinion investigator might affect patient 's participation study Chronic liver disease Concomitant previous treatment investigational drug within 20 day enrolment Previous enrolment present study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Blood pressure reduction</keyword>
	<keyword>combination therapy</keyword>
	<keyword>candesartan cilexetil</keyword>
	<keyword>hydrochlorothiazide</keyword>
</DOC>